Opinion|Videos|January 10, 2025
Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma
Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide an overview of the following emerging BTKi treatment regimens in treatment-naive patients with MCL.
- Acalabrutinib + bendamustine + rituximab
- Acalabrutinib + lenalidomide + rituximab
- Acalabrutinib + umbralisib + ublituximab
- Ibrutinib + rituximab
- Zanubrutinib + rituximab
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5